Leios Therapeutics Announces Exclusive Licensing Agreement and Strategic Investment with Subsidiaries of China Medical System Holdings Ltd. for 10XB-101
Summary
Leios Therapeutics announced an exclusive licensing agreement with subsidiaries of China Medical System Holdings for 10XB-101 in mainland China, Hong Kong, and Macau. CMS also made a strategic equity investment in Leios as part of the transaction. Leios will receive upfront, milestone, and royalty payments while continuing clinical development support for the therapy. The company said trial initiation activities are underway and it expects to start the next trial in early 2027. The deal follows another regional licensing agreement and expands Leios's commercialization footprint in major aesthetics markets.
Funding
Amount
-
Total raised
Date
August 30, 2026
Announcement date
Investors
-
Lead investors
Company
leiostherapeutics.com
Funded company
AskAI Classifications
Sectors
No sectors detected
Functions
No functions detected